Cargando…

Interactome of PTH-Regulated miRNAs and Their Predicted Target Genes for Investigating the Epigenetic Effects of PTH (1–34) in Bone Metabolism

Osteoporosis is a metabolic bone disease that mostly affects the elderly. A lot of drugs are available, mostly with an antiresorptive effect but just a few with an osteoanabolic effect, meaning they promote bone building. PTH (1-34) or teriparatide is an osteoanabolic drug, but its efficacy varies b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vrščaj, Lucija Ana, Marc, Janja, Ostanek, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407897/ https://www.ncbi.nlm.nih.gov/pubmed/36011354 http://dx.doi.org/10.3390/genes13081443

Ejemplares similares

Endogenous PTH Deficiency Impairs Fracture Healing and Impedes the Fracture-Healing Efficacy of Exogenous PTH(1-34)
por: Ren, Yongxin, et al.
Publicado: (2011)

TBP, PPIA, YWHAZ and EF1A1 Are the Most Stably Expressed Genes during Osteogenic Differentiation
por: Franko, Nina, et al.
Publicado: (2022)

Disruption of PTH Receptor 1 in T Cells Protects against PTH-Induced Bone Loss
por: Tawfeek, Hesham, et al.
Publicado: (2010)

PSAT158 Dimeric [Cys25]PTH(1-34) and Monomeric PTH(1-34) Differentially Regulate the Expression of Genes Related to Calcium Homeostasis in Bone and Kidney
por: Lee, Sihoon, et al.
Publicado: (2022)

Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long‐Acting PTH Analog (LA‐PTH)
por: Noda, Hiroshi, et al.
Publicado: (2020)

PTH 1-34 promoted bone formation by regulating iron metabolism in unloading-induced bone loss
por: Che, Jingmin, et al.
Publicado: (2023)

Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis
por: Salave, Sagar, et al.
Publicado: (2023)

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients
por: Zuo, Jiao, et al.
Publicado: (2023)

Continuous infusion of PTH(1–34) delayed fracture healing in mice
por: Yukata, Kiminori, et al.
Publicado: (2018)

PTH [1–34] induced differentiation and mineralization of mandibular condylar cartilage
por: O’ Brien, Mara Heather, et al.
Publicado: (2017)

The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
por: Arlt, Heike, et al.
Publicado: (2019)

Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1–34)
por: Le Henaff, Carole, et al.
Publicado: (2023)

OR07-01 Identification of the First Case of Acquired Autoimmune Parathyroid Hormone (PTH) Resistance Due to PTH1 Receptor (PTH1R) Autoantibodies
por: Mandl, Adel, et al.
Publicado: (2020)

Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range
por: Medas, Fabio, et al.
Publicado: (2019)

Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review
por: Li, Guoqing, et al.
Publicado: (2023)

Simultaneous incorporation of PTH(1–34) and nano-hydroxyapatite into Chitosan/Alginate Hydrogels for efficient bone regeneration
por: Zou, Zhiyuan, et al.
Publicado: (2020)

Graphene Oxide/RhPTH(1-34)/Polylactide Composite Nanofibrous Scaffold for Bone Tissue Engineering
por: Fei, Fan, et al.
Publicado: (2023)

Hypocalcemia after thyroidectomy: iPTH levels and iPTH decline are predictive? Retrospective cohort study()
por: Cannizzaro, Matteo Angelo, et al.
Publicado: (2018)

Case Report: Inactivating PTH/PTHrP Signaling Disorder Type 1 Presenting With PTH Resistance
por: Demaret, Tanguy, et al.
Publicado: (2022)

Exogenous PTH 1-34 Attenuates Impaired Fracture Healing in Endogenous PTH Deficiency Mice via Activating Indian Hedgehog Signaling Pathway and Accelerating Endochondral Ossification
por: Ma, Cheng, et al.
Publicado: (2022)

Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH
por: Vavanikunnel, Janina, et al.
Publicado: (2022)

Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy
por: Lehmann, Gabriele, et al.
Publicado: (2009)

Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
por: O'Brien, Charles A., et al.
Publicado: (2008)

Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH-(1–34)
por: Elder, Grahame, et al.
Publicado: (2008)

Enhanced bone regeneration via local low-dose delivery of PTH(1-34) in a composite hydrogel
por: Zhang, Shanyong, et al.
Publicado: (2023)

Decrease in the expression of the type 1 PTH/PTHrP receptor (PTH1R) on chondrocytes in animals with osteoarthritis
por: Becher, Christoph, et al.
Publicado: (2010)

Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio
por: Yamada, Shunsuke, et al.
Publicado: (2013)

Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH
por: Kuragano, Takahiro, et al.
Publicado: (2013)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Neonatal transient pseudohypoparathyroidism: could it be included among inactivating parathyroid hormone (PTH)/PTH-related protein signalling disorders?
por: De Rose, Domenico Umberto, et al.
Publicado: (2019)

Comparison of Intact PTH and Bio-Intact PTH Assays Among Non-Dialysis Dependent Chronic Kidney Disease Patients
por: Einbinder, Yael, et al.
Publicado: (2017)

Chemical Characterization and Quantification of Circulating Intact PTH and PTH Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure
por: Kritmetapak, Kittrawee, et al.
Publicado: (2021)

Modifications in Bone Matrix of Estrogen-Deficient Rats Treated with Intermittent PTH
por: Pacheco-Costa, Rafael, et al.
Publicado: (2015)

SLPI is a critical mediator that controls PTH-induced bone formation
por: Morimoto, Akito, et al.
Publicado: (2021)

Catabolic Effects of Human PTH (1–34) on Bone: Requirement of Monocyte Chemoattractant Protein-1 in Murine Model of Hyperparathyroidism
por: Siddiqui, Jawed A., et al.
Publicado: (2017)

Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling
por: Pawlak, Krystyna, et al.
Publicado: (2021)

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
por: Pearson, Richard G., et al.
Publicado: (2019)

Recombinant PTH associated with hypercalcaemia and renal failure
por: Ayasreh, Nadia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f80f43vl6agagqmqpfk2hvg7ie